Drugs / Autologous PRP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03026855 | Jun 2014 → Apr 2016 | chronic ulcer of skin | TotipotentRX Cell Therapy Pvt. Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous PRP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03026855 ↗ |
| Known as | Platelet Rich Plasma (PRP) | “Application of autologous Platelet Rich Plasma (PRP) has been a major breakthrough for the treatment of non-healing and diabetic foot ulcers, as it is an easy and...” PMID 28241824 ↗ Feb 2017 |
| Modality | Cell therapy | “Cellular therapies using Autologous Platelet Rich Plasma provides new options for wound healing.” NCT03026855 ↗ |
| Route | Subcutaneous | “will be injected subcutaneously around the periphery of the wound/ulcer” NCT03026855 ↗ |